Abstract:ID 54817 Poster Board 319 Objective: Globally, cancer is a major burden of disease threatening human health. To date, immune checkpoint inhibitors are monoclonal antibodies that cover various cancer indications as monotherapy or in combination, have revealed remarkable clinical success in a wide range of solid tumors and hematologic malignancies. Due to the inherent limitations of antibodies, it is reasonable to consider discovering orally bioavailable small molecule inhibitors that target programmed cell death protein 1/programmable death-ligand 1 (PD-1/PD-L1) signaling pathway as alternative. The aim of this study is to mainly focus on computer aided drug design (CADD) process to predict the possible small molecules that can interact with PD-1, and further serve as starting points to design potential safe and efficacious compounds in cancer treatment. Methods: Possible ligand binding sites on the PD-1 protein were initially predicted by DoGSiteScorer, FTsite and PrankWeb servers. The 6 highest-ranked clusters based on the "druggability" score from PocketQuery were selected as queries for pharmacophore-based virtual screening using ZincPharmer. Drug likeness property assessment and ADME-tox prediction have been performed by using SwissADME and ADMETlab. Results: 30 hit compounds were initially retrieved by pharmacophore-based virtual screening. Thereafter, 5 compounds with lowest Gibb's free energy (G) values, namely ZINC85867378, ZINC16267039, ZINC64219346, ZINC68604154 and ZINC20576138, have been chosen for further evaluation. ZINC68604154 showed G of -9.07 kcal/mol and appeared to have reasonable oral bioavailability, low drug-drug interaction potential, and low toxicity risk. Conclusion: This study establishes the workflow combining pharmacophore virtual screening, molecular docking, and absorption, distribution, metabolism, excretion - toxicity (ADMET) prediction to identify possible small molecules that can interact with PD-1. The identified compounds might serve as starting points to design potential safe and efficacious molecules in cancer Immunotherapy. Further evaluation through in vitro and in vivo is necessary to optimize drug properties.

Chemical and Physical Metrics in Establishing Benchmarks for Chemotherapy Drug Efficacy

Analysis of Cytotoxic Effects of Chemotherapeutic Agents for Gastrointestinal Cancer with Cell-based Impedance Biosensor

Synergy Between Experiments and Computations: A Green Channel for Revealing Metabolic Mechanism of Xenobiotics in Chemical Toxicology

Statistical Evaluation of Cancer Drugs by QSPR Modeling

An unbiased metric of antiproliferative drug effect in vitro

Comparison of Cytotoxicity Evaluation of Anticancer Drugs between Real-Time Cell Analysis and CCK-8 Method

Personalizing chemotherapy dosing using pharmacological methods

A New Metric Quantifying Chemical and Biological Property of Small Molecule Metabolites and Drugs

Measuring the Enzymatic Activity of Clinically Important Proteins in Single Cells

Quantifying Cancer Drug Targetability across Biochemical Pathways

Dynamical behavior-based approach for the evaluation of treatment efficacy: The case of immuno-oncology

Physiochemical properties optimization of synthetic bio-destructible 2,6-bisarylidene-4-(t.-butyl)cyclohexanones to select a potential anti-cancer drug contender

Using mathematical modeling to estimate time-independent cancer chemotherapy efficacy parameters

A Computational Approach to Identify Small Molecules Interact with Crystal Structure of Programmed Cell Death Protein 1 as Potential Therapeutics for Cancer Immunotherapy

Pharmacodynamic Modeling to Evaluate the Impact of Cimetidine, an OCT2 Inhibitor, on the Anticancer Effects of Cisplatin

Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action

A Simple and Efficient Metric Quantifying Druggable Property of Chemical Small Molecules

A Comparative Clinical Pharmacology Analysis of FDA-Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

Quantifying Imaging Agent Binding and Dissociation in 3-D Cancer Spheroid Tissue Culture Using Paired-Agent Principles

Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.